These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 2777040)
1. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040 [TBL] [Abstract][Full Text] [Related]
2. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665 [TBL] [Abstract][Full Text] [Related]
3. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Hirschowitz BI; Simmons J; Mohnen J Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694 [TBL] [Abstract][Full Text] [Related]
5. Role of acid suppressants in patients with Zollinger-Ellison syndrome. Maton PN Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671 [TBL] [Abstract][Full Text] [Related]
6. Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Vinayek R; Frucht H; London JF; Miller LS; Stark HA; Norton JA; Cederberg C; Jensen RT; Gardner JD; Maton PN Gastroenterology; 1990 Jul; 99(1):10-6. PubMed ID: 1971604 [TBL] [Abstract][Full Text] [Related]
7. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. Meijer JL; Jansen JB; Lamers CB Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060 [TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754 [TBL] [Abstract][Full Text] [Related]
9. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445 [TBL] [Abstract][Full Text] [Related]
10. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548 [TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Vinayek R; Amantea MA; Maton PN; Frucht H; Gardner JD; Jensen RT Gastroenterology; 1991 Jul; 101(1):138-47. PubMed ID: 2044903 [TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Hirschowitz BI; Haber MM Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. Corleto V; Annibale B; D'Ambra G; Saggioro A; Ferrua B; Cassetta MR; Delle Fave G Aliment Pharmacol Ther; 1993 Apr; 7(2):167-73. PubMed ID: 8485270 [TBL] [Abstract][Full Text] [Related]
15. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514 [TBL] [Abstract][Full Text] [Related]
16. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936 [TBL] [Abstract][Full Text] [Related]
17. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418 [TBL] [Abstract][Full Text] [Related]
18. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Metz DC; Pisegna JR; Fishbeyn VA; Benya RV; Feigenbaum KM; Koviack PD; Jensen RT Gastroenterology; 1992 Nov; 103(5):1498-508. PubMed ID: 1426868 [TBL] [Abstract][Full Text] [Related]
19. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Stewart CA; Termanini B; Sutliff VE; Serrano J; Yu F; Gibril F; Jensen RT Aliment Pharmacol Ther; 1998 Jan; 12(1):83-98. PubMed ID: 9692706 [TBL] [Abstract][Full Text] [Related]
20. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Metz DC; Pisegna JR; Ringham GL; Feigenbaum K; Koviack PD; Maton PN; Gardner JD; Jensen RT Dig Dis Sci; 1993 Feb; 38(2):245-56. PubMed ID: 8425437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]